After Genmab’s exit two more ADCs enter human trials.
ApexOnco Front Page
Recent articles
New pivotal trials of HRS-8080 are planned in first-line and adjuvant breast cancer.
The company takes a PD-L1 x VEGF asset into phase 3.
A new phase 3, Manifest-3, will start in April to support US filing.
New first-in-human study initiations feature yet more in vivo Car assets.
Intismeran autogene’s Interpath-001 trial reads out this year.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
The biotech licenses a China-developed anti-B7-H3 ADC.
